English
Bl-iżvilupp mgħaġġel tal-industrija bijofarmaċewtika, l-użu tat-teknoloġija tal-kultura taċ-ċelluli biex twettaq riċerka dwar vaċċini, antikorpi monoklonali u mediċini oħra saret xejra. Barra minn hekk, il-fabbrika taċ-ċelluli tista 'tintuża wkoll għal produzzjoni fuq skala kbira ta' vaċċin MMR, vaċċin tal-epatite A, vaċċin tal-poljo, eċċ. Bl-iżvilupp mgħaġġel tat-teknoloġija bijomedika, l-ambitu tal-applikazzjoni ta’ dan il-konsumabbli se jsir ukoll usa’ u usa’. huma konsumabbli komunement użati fil-kultura taċ-ċelluli fuq skala kbira, li għandhom rwol importanti fil-produzzjoni fuq skala kbira ta 'vaċċini kontra l-variċella. virus taż-żoster. Is-sintomi kliniċi huma deni, prinċipalment macules, papules, vesicles u scabs f'lottijiet, u anke mewt f'każijiet severi. Il-vaċċin tal-ġidri r-riħ huwa l-aktar mod sikur u effettiv biex jipprevjeni l-ġidri r-riħ. Il-vaċċin tal-variċella jadotta r-razza attenwata tal-virus tal-variċella OKa, li huwa komunement użat fid-dinja, u huwa magħmul minn kultura ta 'ċelluli diploid tal-bniedem MRC-5. Id-dehra tal-prodott imnixxef bil-friża hija korp maħlul abjad ħalib, u huwa likwidu isfar ċar wara li jinħall. Li tikseb il-vaċċin tal-ġidri r-riħ mhux biss tipproteġi kontra l-ġidri r-riħ, iżda wkoll tipprevjeni l-kumplikazzjonijiet mill-ħruq ta 'Sant'Antnin tal-ġidri r-riħ. tiżdied, u għandha volum kbir tas-suq. Diversi esperjenzi prattiċi wrew ukoll li, meta mqabbla ma 'konsumabbli ta' kultura oħra, l-użu ta 'fabbriki taċ-ċelluli għal produzzjoni fuq skala kbira ta' vaċċin tal-variċella għandu l-vantaġġi ta 'inqas tniġġis, rendiment għoli tal-prodott, varjabilità żgħira minn lott għal lott, u ħin qasir ta' tħaddim . Metodu importanti tal-kultura taċ-ċelluli għall-intrapriżi.
Chickenpox is a highly contagious acute infectious disease caused by the varicella-zoster virus. The clinical symptoms are fever, mainly macules, papules, vesicles and scabs in batches, and even death in severe cases. The chickenpox vaccine is the safest and most effective way to prevent chickenpox. The varicella vaccine adopts the attenuated strain of varicella virus OKa, which is commonly used in the world, and is made by MRC-5 human diploid cell culture. The appearance of the freeze-dried product is a milky white loose body, and it is a pale yellow liquid after dissolving. Getting the chickenpox vaccine not only protects against chickenpox, but also prevents complications from chickenpox shingles.
Since August 1, 2018, the varicella vaccine has been included in the Shanghai Municipal Immunization Plan, and people's attention to the varicella vaccine has continued to increase, and it has a large market volume. Various practical experiences have also proved that, compared with other culture consumables, the use of cell factories for large-scale production of varicella vaccine has the advantages of less pollution, high product yield, small batch-to-batch variability, and short operation time. An important cell culture method for enterprises.
In addition, the cell factory can also be used for large-scale production of MMR vaccine, hepatitis A vaccine, polio vaccine, etc. With the rapid development of biomedical technology, the application scope of this consumable will also become wider and wider.
The FAI climbed 5.9 percent year-on-year in the first 11 months of 2018, quickening from the 5.7-percent growth in Jan-Oct, the National Bureau of Statistics (NBS) said Friday in an online statement.
The key indicator of investment, dubbed a major growth driver, hit the bottom in August and has since started to rebound steadily.
In the face of emerging economic challenges home and abroad, China has stepped up efforts to stabilize investment, in particular rolling out measures to motivate private investors and channel funds into infrastructure.
Friday's data showed private investment, accounting for more than 60 percent of the total FAI, expanded by a brisk 8.7 percent.
NBS spokesperson Mao Shengyong said funds into weak economic links registered rapid increases as investment in environmental protection and agriculture jumped 42 percent and 12.5 percent respectively, much faster than the average.
In breakdown, investment in high-tech and equipment manufacturing remained vigorous with 16.1-percent and 11.6-percent increases respectively in the first 11 months. Infrastructure investment gained 3.7 percent, staying flat. Investment in property development rose 9.7 percent, also unchanged.